This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Should You Buy Sequans (SQNS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
SQNSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion
by Zacks Equity Research
Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.
NVSPositive Net Change DVAXPositive Net Change GILDPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19
by Zacks Equity Research
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
GSKPositive Net Change DVAXPositive Net Change GILDPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study
by Zacks Equity Research
Bristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and clinically meaningful improvement in recurrence-Free survival (RFS) in patients with Stage IIB/C melanoma.
BMYPositive Net Change DVAXPositive Net Change MRKPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
by Zacks Equity Research
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
REGNPositive Net Change DVAXPositive Net Change BAYRYNegative Net Change ADVMPositive Net Change
biotechnology biotechs gene-therapy pharmaceuticals
Should You Buy Earthstone Energy (ESTE) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ESTENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
REGNPositive Net Change BMYPositive Net Change NVAXPositive Net Change AMLXPositive Net Change AKROPositive Net Change
biotechnology biotechs
Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players
by Zacks Equity Research
Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.
GSKPositive Net Change DVAXPositive Net Change GILDPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study
by Zacks Equity Research
Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).
DVAXPositive Net Change ZEALPositive Net Change BOLTPositive Net Change EWTXPositive Net Change
biotechnology biotechs
After Golden Cross, YPF Sociedad Anonima (YPF)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
YPFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Civitas Resources (CIVI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CIVINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Amtech Systems (ASYS)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ASYSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
FlexShopper Inc. (FPAY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FPAYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up
by Zacks Equity Research
FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.
ABBVNegative Net Change AGENPositive Net Change RVNCPositive Net Change
biotechnology biotechs pharmaceuticals
Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success
by Zacks Equity Research
Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.
REGNPositive Net Change RHHBYPositive Net Change DVAXPositive Net Change BAYRYNegative Net Change
biotechnology biotechs pharmaceuticals
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
by Zacks Equity Research
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
CPRXPositive Net Change AERIPositive Net Change SLNOPositive Net Change
biotechnology medical pharmaceuticals
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
by Zacks Equity Research
Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.
BMYPositive Net Change DVAXPositive Net Change EXELPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.
GSKPositive Net Change DVAXPositive Net Change GILDPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More
by Zacks Equity Research
Regulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week.
NVONegative Net Change GILDPositive Net Change VRTXNegative Net Change SPROPositive Net Change
biotechnology biotechs pharmaceuticals
Spero (SPRO) Up Following Positive FDA Update for UTI Drug
by Zacks Equity Research
Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.
DVAXPositive Net Change PFEPositive Net Change SPROPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Company News for Sep 7, 2022
by Zacks Equity Research
Companies In The News Are: BBBY, SGFY, CVS, LOW, ILMN.
LOWPositive Net Change ILMNPositive Net Change CVSPositive Net Change BBBYPositive Net Change
biotechnology retail
5 Top Stocks to Buy on New Analysts' Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Napco Security (NSSC), Proto Labs (PRLB), Clear Secure (YOU), AVEO and Mind Medicine (MNMD).
AVEOPositive Net Change PRLBNegative Net Change NSSCPositive Net Change MNMDNegative Net Change YOUNegative Net Change
biotechnology biotechs finance genetic-testing industrial-products
Eneti (NETI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy AES (AES) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AESPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Advanced Drainage Systems (WMS)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
WMSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines